Peer-reviewed article
Systematic review of Dengue Vaccines (CYD-TDV and TAK-003) in children: efficacy, immunogenicity, safety and challenges
Muhammad Faheem Afzal ·
Summary
Written by AI, not yet AICS's view ·Key points
Limitations
Abstract
Background: Vaccination has emerged as a promising strategy for dengue prevention, with several vaccines undergoing clinical evaluation. This systematic review is aimed to synthesize the current literature on the efficacy, immunogenicity, and safety of dengue vaccines, particularly CYD-TDV (Dengvaxia®) and TAK-003 (Qdenga®) in children. Methods: PRISMA guidelines were used to guide standard processes for data extraction during a systematic literature search. To find pertinent research published, electronic databases such as PubMed, Medline, Embase, and the Cochrane Library were searched up to 2024. Observational studies, randomized controlled trials, meta-analyses and systematic reviews, focused on children (<18 years of age) were considered eligible for inclusion. The CYD-TDV vaccination and TAK-003 were evaluated for their overall and serotype-specific effectiveness. Results: Key findings regarding vaccine efficacy, immunogenicity, and safety in children are summarized in this review. CYD-TDV, despite its efficacy in dengue-experienced individuals, long term safety data demonstrated that this vaccine increased the risk of more severe symptoms upon dengue infection in individuals who were dengue-naive and in children <9 years of age. TAK-003 has shown promising results, with an overall efficacy in preventing symptomatic dengue in children and adolescents. Conclusion: Dengue vaccines represent a promising tool for dengue prevention in children. While vaccine efficacy and safety issues remain, ongoing research and innovation hold promise for the safer and more effective dengue vaccines development.